Diosmin

Identification

Summary

Diosmin is a citrus flavonoid medication used to support vascular health.

Generic Name

Diosmin

DrugBank Accession Number

DB08995

Background

Chronic venous insufficiency is a common condition the western population. Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease.⁶

Diosmin is a bioflavonoid isolated from various plants or synthesized from hesperidin. It is used for the improvement of capillary fragility or venous insufficiency, including chronic venous insufficiency (CVI) and hemorrhoids. Diosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.^7,16,20

Type

Small Molecule

Groups

Approved, Investigational

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Diosmin (DB08995)

×

Close

Weight

Average: 608.5447
Monoisotopic: 608.174120354

Chemical Formula

C₂₈H₃₂O₁₅

Synonyms

• 3',5,7-trihydroxy-4'-methoxyflavone 7-rhamnoglucoside
• 3',5,7-trihydroxy-4'-methoxyflavone-7-rutinoside
• diosmetin 7-neohesperidoside
• Diosmetin 7-O-rutinoside
• Diosmin
• Diosmina
• Diosmine
• Diosminum

External IDs

• SE 4601

Pharmacology

Indication

Diosmin is used over-the-counter alone or with ingredients such as hesperidin and diosmetin to support vein and capillary function.^17,18

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

• Capillary fragility
• Circulatory Function
• Haemorrhoids
• Venous Insufficiency
• Healthy capillaries
• Healthy veins

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Diosmin is a venoactive drug supporting circulatory health through various actions on blood vessels; it supports lymphatic drainage and improves microcirculation while increasing venous tone and elasticity. For these reasons, diosmin is frequently taken by individuals with chronic venous disease to support vascular health and has been demonstrated to improve quality of life.^3,17 In addition to the above effects, diosmin exerts antioxidant activity and scavenges oxygen free radicals, reducing levels of oxidative stress normally detected through biomarkers such as prostaglandins isoprostane precursors.¹

In one clinical study, mean content of TNF alpha, VEGF-C, VEGF-A IL-6, in addition to FGF2 were decreased by after the therapy with diosmin; findings were statistically significant. Additionally, a decrease in edema and mean leg circumference of patients taking diosmin for three months was observed in a clinical study.³ Diosmin has been demonstrated to enhance the metabolism of glucose in diabetic disorders.¹⁴

Mechanism of action

Diosmin helps to maintain circulatory system structure and function, particularly vein strength and competence.¹⁷ The molecular mechanism of action of diosmin has not been established.³ Several resources indicate that diosmin binds to the aryl hydrocarbon receptor, however clinical relevance to vascular function is unknown.^11,12,13 One study demonstrates that oral diosmin exerts effects on the in vitro metabolism of noradrenaline by varicose veins, potentially benefitting vascular health.⁹

Target	Actions	Organism
UAryl hydrocarbon receptor	agonist	Humans

Absorption

Diosmin is rapidly absorbed in the gastrointestinal tract.² After a 900 mg single oral dose in a study using liquid chromatography with tandem mass spectrometry (LC-MS/MS) method, Cmax was 4.2±3.8 ^ng·mL-1, Tmax was 18.7±9.9 hours, and AUC0~96 was 185.4±166.2 ^ng·mL-1 in healthy volunteers.¹⁵ Another pharmacokinetic study of 5 adults revealed a Cmax of 417±94.1 ng/dL.¹⁸

Volume of distribution

A pharmacokinetic study of 5 adults revealed a volume of distribution of 62.1±7.9 L.¹⁸

Protein binding

Diosmin binds to serum albumin.⁴

Metabolism

Degradation products of diosmin such as alkyl-phenolic acids confirm a metabolic pattern similar to that of other flavonoids.²

Route of elimination

Pharmacokinetic data show absence of urinary elimination for diosmin and its aglycone diosmetin. Minor metabolites are found to be eliminated in the urine as glucuronic acid conjugates.²

Half-life

Diosmin half-life ranges from 26 to 43 hours.² One study using a liquid chromatography with tandem mass spectrometry (LC-MS/MS) method after a single 900 mg dose of diosmin demonstrated a half-life of 60.2±85.7 hours in healthy volunteers.¹⁵

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

The LD50 of diosmin is >3g/kg in animal studies, with an LD50 of great than 3000 mg/kg in rats.¹⁵ No cases of overdose have been reported, however, an overdose is likely to result in gastrointestinal effects such as nausea, dyspepsia, vomiting, and diarrhea.²⁰

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Diosmin.
Abrocitinib	The metabolism of Abrocitinib can be decreased when combined with Diosmin.
Acalabrutinib	The metabolism of Acalabrutinib can be decreased when combined with Diosmin.
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Diosmin.
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Diosmin.
Acetohexamide	The metabolism of Acetohexamide can be decreased when combined with Diosmin.
Acetylsalicylic acid	The metabolism of Acetylsalicylic acid can be decreased when combined with Diosmin.
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Diosmin.
Albendazole	The metabolism of Albendazole can be decreased when combined with Diosmin.
Alectinib	The metabolism of Alectinib can be decreased when combined with Diosmin.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

• Take with or without food.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

International/Other Brands

Barosmin / Dalfon (Servier) / Detralex / Diosven / Dioven / Diovenor / Flebosmil / Flebosten / Insuven / Litosmil / Ven-Detrex / Venosmine

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
DAFLON FILM-COATED TABLET 1000 mg	Tablet, film coated	900 mg	Oral	SERVIER (S) PTE LTD	2019-04-16	Not applicable
RUVENTIN FILM COATED TABLET 500MG	Tablet, film coated	450 mg	Oral	PHARMAZEN MEDICALS PTE LTD	2020-12-29	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
AVEFLON TABLET	Diosmin (450 mg) + Hesperidin (50 mg)	Tablet, film coated	Oral	APEX PHARMACY MARKETING SDN. BHD.	2020-09-08	Not applicable
Daflon 1000mg Film-Coated Tablet	Diosmin (900 mg) + Hesperidin (100 mg)	Tablet, film coated	Oral	SERVIER MALAYSIA SDN BHD	2020-09-08	Not applicable
daflon 500mg tablets	Diosmin (450 mg) + Hesperidin (50 mg)	Tablet, film coated	Oral	SERVIER MALAYSIA SDN BHD	2020-09-08	Not applicable
DAFLON TABLET 500 mg	Diosmin (450 mg) + Hesperidin (50 mg)	Tablet, sugar coated	Oral	SERVIER (S) PTE LTD	1988-05-12	Not applicable
Davmorid Film Coated Tablet	Diosmin (450 mg) + Hesperidin (50 mg)	Tablet, film coated	Oral	Y.S.P. INDUSTRIES (M) SDN BHD	2020-09-08	Not applicable
DIOFLEX TABLET	Diosmin (450 mg) + Hesperidin (50 mg)	Tablet	Oral	PRIME PHARMACEUTICAL SDN. BHD.	2020-09-08	Not applicable
DIOKERN 450 MG/50 MG FILM KAPLI TABLET,30 ADET	Diosmin (450 mg) + Hesperidin (50 mg)	Tablet, coated	Oral	DROGSAN İLAÇLARI SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
DIOKERN 450 MG/50 MG FILM KAPLI TABLET,60 ADET	Diosmin (450 mg) + Hesperidin (50 mg)	Tablet, coated	Oral	DROGSAN İLAÇLARI SAN. VE TİC. A.Ş.	2020-08-14	Not applicable
DIOSMINA 450 MG HESPERIDINA 50 MG TABLETA RECUBIERTA	Diosmin (450 mg) + Hesperidin (50 mg)	Tablet, coated	Oral	LABORATORIO FRANCO COLOMBIANO - LAFRANCOL S.A.S.	2012-11-15	Not applicable
DIOSMINA 450 MG/HESPERIDINA 50 MG TABLETAS RECUBIERTAS	Diosmin (450 mg) + Hesperidin (50 mg)	Tablet, coated	Oral	SANOFI - AVENTIS DE COLOMBIA S.A.	2010-03-24	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Analpram Advanced	Diosmin (600 mg/1) + Calcium magnesium potassium carbonate chloride hydroxide (30 mg/1) + Hydrocortisone acetate (25 mg/1g) + Pramoxine hydrochloride (10 mg/1g)	Kit	Oral; Topical	Sebela Pharmaceuticals Inc.	2015-08-07	2017-02-28
Analpram Advanced	Diosmin (600 mg/1) + Calcium magnesium potassium carbonate chloride hydroxide (30 mg/1) + Hydrocortisone acetate (25 mg/1g) + Pramoxine hydrochloride (10 mg/1g)	Kit	Topical	Sebela Pharmaceuticals Inc.	2015-08-07	2016-08-31
Analpram Advanced	Diosmin (600 mg/1) + Calcium magnesium potassium carbonate chloride hydroxide (30 mg/1) + Hydrocortisone acetate (25 mg/1g) + Pramoxine hydrochloride (10 mg/1g)	Kit	Oral; Topical	Sebela Pharmaceuticals Inc.	2015-08-07	2017-02-28

Categories

ATC Codes

C05CA03 — Diosmin

• C05CA — Bioflavonoids
• C05C — CAPILLARY STABILIZING AGENTS
• C05 — VASOPROTECTIVES
• C — CARDIOVASCULAR SYSTEM

C05CA53 — Diosmin, combinations

• C05CA — Bioflavonoids
• C05C — CAPILLARY STABILIZING AGENTS
• C05 — VASOPROTECTIVES
• C — CARDIOVASCULAR SYSTEM

Drug Categories

• Benzopyrans
• Capillary Stabilizing Agents
• Chromones
• Cytochrome P-450 CYP2C9 Inhibitors
• Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)
• Cytochrome P-450 CYP2E1 Inhibitors
• Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)
• Cytochrome P-450 Enzyme Inhibitors
• Flavones
• Flavonoids
• Heterocyclic Compounds, Fused-Ring
• OATP1B1/SLCO1B1 Inhibitors
• P-glycoprotein inhibitors
• Pyrans
• Vasoprotectives

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as flavonoid-7-o-glycosides. These are phenolic compounds containing a flavonoid moiety which is O-glycosidically linked to carbohydrate moiety at the C7-position.

Kingdom

Organic compounds

Super Class

Phenylpropanoids and polyketides

Class

Flavonoids

Sub Class

Flavonoid glycosides

Direct Parent

Flavonoid-7-O-glycosides

Alternative Parents

4'-O-methylated flavonoids / 3'-hydroxyflavonoids / 5-hydroxyflavonoids / Flavones / Phenolic glycosides / O-glycosyl compounds / Chromones / Disaccharides / Methoxyphenols / Phenoxy compounds / Methoxybenzenes / Anisoles / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Pyranones and derivatives / Alkyl aryl ethers / Oxanes / Vinylogous acids / Heteroaromatic compounds / Secondary alcohols / Acetals / Oxacyclic compounds / Polyols / Hydrocarbon derivatives / Organic oxides

show 15 more

Substituents

1-benzopyran / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 3'-hydroxyflavonoid / 4p-methoxyflavonoid-skeleton / 5-hydroxyflavonoid / Acetal / Alcohol / Alkyl aryl ether / Anisole / Aromatic heteropolycyclic compound / Benzenoid / Benzopyran / Chromone / Disaccharide / Ether / Flavone / Flavonoid-7-o-glycoside / Glycosyl compound / Heteroaromatic compound / Hydrocarbon derivative / Hydroxyflavonoid / Methoxybenzene / Methoxyphenol / Monocyclic benzene moiety / O-glycosyl compound / Organic oxide / Organic oxygen compound / Organoheterocyclic compound / Organooxygen compound / Oxacycle / Oxane / Phenol / Phenol ether / Phenolic glycoside / Phenoxy compound / Polyol / Pyran / Pyranone / Secondary alcohol / Vinylogous acid

show 31 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

rutinoside, disaccharide derivative, monomethoxyflavone, glycosyloxyflavone, dihydroxyflavanone (CHEBI:4631) / flavones (C10039)

Affected organisms

Not Available

Chemical Identifiers

UNII

7QM776WJ5N

CAS number

520-27-4

InChI Key

GZSOSUNBTXMUFQ-YFAPSIMESA-N

InChI

InChI=1S/C28H32O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-8,10,19,21-30,32-37H,9H2,1-2H3/t10-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1

IUPAC Name

5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4H-chromen-4-one

SMILES

COC1=C(O)C=C(C=C1)C1=CC(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)C=C2O1

References

Synthesis Reference

Rajiv Sakhardande, Manmohan Nimbalkar, Navin Khatri, Subarao Patil, Santosh Bhalekar, Rajendra Patil, Pandharinath Firake (2011). Process for the preparation of diosmin (WO2010092592A2).IFI CLAIMS PATENT SERVICES.https://patents.google.com/patent/WO2010092592A2/en

General References

1. Feldo M, Wozniak M, Wojciak-Kosior M, Sowa I, Kot-Wasik A, Aszyk J, Bogucki J, Zubilewicz T, Bogucka-Kocka A: Influence of Diosmin Treatment on the Level of Oxidative Stress Markers in Patients with Chronic Venous Insufficiency. Oxid Med Cell Longev. 2018 Aug 28;2018:2561705. doi: 10.1155/2018/2561705. eCollection 2018. [Article]
2. Cova D, De Angelis L, Giavarini F, Palladini G, Perego R: Pharmacokinetics and metabolism of oral diosmin in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1992 Jan;30(1):29-33. [Article]
3. Feldo M, Wojciak-Kosior M, Sowa I, Kocki J, Bogucki J, Zubilewicz T, Kesik J, Bogucka-Kocka A: Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis. Molecules. 2019 Sep 12;24(18). pii: molecules24183316. doi: 10.3390/molecules24183316. [Article]
4. Barreca D, Lagana G, Bruno G, Magazu S, Bellocco E: Diosmin binding to human serum albumin and its preventive action against degradation due to oxidative injuries. Biochimie. 2013 Nov;95(11):2042-9. doi: 10.1016/j.biochi.2013.07.014. Epub 2013 Jul 22. [Article]
5. Gzona Bajraktari, Johanna Weiss: The aglycone diosmetin has the higher perpetrator drug-drug interaction potential compared to the parent flavone diosmin Journal of Functional Foods. [Article]
6. Sliva J: Diosmin - still an important modality in the treatment of venous insufficiency. Vnitr Lek. 2019 Summer;65(7-8):524-526. [Article]
7. Milano G, Leone S, Fucile C, Zuccoli ML, Stimamiglio A, Martelli A, Mattioli F: Uncommon serum creatine phosphokinase and lactic dehydrogenase increase during diosmin therapy: two case reports. J Med Case Rep. 2014 Jun 16;8:194. doi: 10.1186/1752-1947-8-194. [Article]
8. Boisnic S, Branchet MC, Gouhier-Kodas C, Verriere F, Jabbour V: Anti-inflammatory and antiradical effects of a 2% diosmin cream in a human skin organ culture as model. J Cosmet Dermatol. 2018 Oct;17(5):848-854. doi: 10.1111/jocd.12778. Epub 2018 Sep 10. [Article]
9. Araujo D, Viana F, Osswald W: Diosmin therapy alters the in vitro metabolism of noradrenaline by the varicose human saphenous vein. Pharmacol Res. 1991 Oct;24(3):253-6. doi: 10.1016/1043-6618(91)90088-f. [Article]
10. Bogucka-Kocka A, Wozniak M, Feldo M, Kockic J, Szewczyk K: Diosmin--isolation techniques, determination in plant material and pharmaceutical formulations, and clinical use. Nat Prod Commun. 2013 Apr;8(4):545-50. [Article]
11. Zhang S, Qin C, Safe SH: Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ Health Perspect. 2003 Dec;111(16):1877-82. [Article]
12. Ciolino HP, Wang TT, Yeh GC: Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity. Cancer Res. 1998 Jul 1;58(13):2754-60. [Article]
13. Lee J, Song KM, Jung CH: Diosmin restores the skin barrier by targeting the aryl hydrocarbon receptor in atopic dermatitis. Phytomedicine. 2021 Jan;81:153418. doi: 10.1016/j.phymed.2020.153418. Epub 2020 Nov 25. [Article]
14. Hsu CC, Lin MH, Cheng JT, Wu MC: Antihyperglycaemic action of diosmin, a citrus flavonoid, is induced through endogenous beta-endorphin in type I-like diabetic rats. Clin Exp Pharmacol Physiol. 2017 May;44(5):549-555. doi: 10.1111/1440-1681.12739. [Article]
15. T.T. Zhu, M-L. Du, H.M. Su, Lun Yang: Pharmacokinetics of diosmin tablets in healthy volunteers Chinese Journal of New Drugs. [Article]
16. Ronald Watson, Victor Preedy (2019). Bioactive Food as Dietary Interventions for Diabetes (2nd ed.). Academic Press. [ISBN:978-0-12-813822-9]
17. Xymogen product monograph: DIOVASC (Diosmin and hesperidin) oral capsules [Link]
18. DailyMed label: VASCULERA (diosmiplex) oral tablets [Link]
19. ECHA Europa Registration Dossier: Diosmin [Link]
20. Summary of Product Characteristics: Diosmin [Link]

External Links

KEGG Drug

D07858

KEGG Compound

C10039

PubChem Compound

5281613

PubChem Substance

310264956

ChemSpider

4444932

BindingDB

153267

RxNav

3489

ChEBI

4631

ChEMBL

CHEMBL231884

ZINC

ZINC000004098512

Drugs.com

Drugs.com Drug Page

Wikipedia

Diosmin

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Basic Science	Chronic Venous Insufficiency (CVI)	1
4	Completed	Treatment	Deep Vein Thrombosis / Post Thrombotic Syndrome	1
4	Completed	Treatment	Venous Insufficiency	1
4	Not Yet Recruiting	Treatment	Pelvic Congestive Syndrome / Pelvic Varicose Veins / Venous Disease	1
4	Recruiting	Treatment	Lymphedema Lower Extremity	1
3	Completed	Treatment	Chronic Venous Disease of Lower Limbs	1
3	Not Yet Recruiting	Prevention	Vinca Alkaloid Adverse Reaction	1
3	Unknown Status	Treatment	Chronic Venous Insufficiency (CVI) / Disease	1
3	Unknown Status	Treatment	Chronic Venous Insufficiency (CVI) / Haemorrhoids	1
2, 3	Completed	Prevention	Infertility	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Powder, for suspension	Oral
Kit	Oral; Topical
Kit	Topical
Tablet, coated	Oral
Tablet, film coated	Oral
Tablet, film coated	Oral
Tablet, film coated	Oral	50 mg
Tablet, film coated	Oral	500 MG
Tablet, film coated	Oral	900 mg
Tablet, sugar coated	Oral	450 mg
Tablet, coated	Oral
Cream	Topical
Granule
Tablet	Oral
Cream	Topical	5 g/100g
Cream	Topical	5 %
Granule, for solution	Oral	450 MG
Tablet	Oral	150 MG
Tablet	Oral	300 MG
Tablet	Oral	450 mg
Tablet, film coated	Oral	600 mg
Tablet, film coated	Oral	450 mg
Tablet, film coated	Oral	450 mg
Tablet	Oral
Tablet	Oral	450 mg
Powder, for suspension	Oral
Capsule		300 MG
Cream	Topical	4 %
Granule, for solution	Oral	300 mg
Powder, for suspension	Oral	300 MG
Powder, for suspension	Oral	450 MG
Tablet, coated	Oral	500 mg
Tablet, coated	Oral	450 mg

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	277-278	https://www.chemsrc.com/en/cas/520-27-4_329710.html
boiling point (°C)	926.8±65.0	https://www.chemsrc.com/en/cas/520-27-4_329710.html
water solubility	0.019 ± 0.005 mg/L	https://echa.europa.eu/registration-dossier/-/registered-dossier/21071/4/9
logP	2.05	https://www.chemsrc.com/en/cas/520-27-4_329710.html
pKa	6.10±0.40	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6443258.htm

Predicted Properties

Property	Value	Source
Water Solubility	1.54 mg/mL	ALOGPS
logP	0.08	ALOGPS
logP	-0.44	ChemAxon
logS	-2.6	ALOGPS
pKa (Strongest Acidic)	7.31	ChemAxon
pKa (Strongest Basic)	-3.6	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	15	ChemAxon
Hydrogen Donor Count	8	ChemAxon
Polar Surface Area	234.29 Å2	ChemAxon
Rotatable Bond Count	7	ChemAxon
Refractivity	142.39 m3·mol-1	ChemAxon
Polarizability	58.93 Å3	ChemAxon
Number of Rings	5	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
MS/MS Spectrum - ESI-TOF 20V, Negative	LC-MS/MS	Not Available
MS/MS Spectrum - ESI-TOF 10V, Negative	LC-MS/MS	Not Available
MS/MS Spectrum - ESI-TOF 40V, Negative	LC-MS/MS	Not Available
MS/MS Spectrum - ESI-TOF 20V, Negative	LC-MS/MS	Not Available
MS/MS Spectrum - ESI-TOF 10V, Negative	LC-MS/MS	Not Available
MS/MS Spectrum - ESI-TOF 40V, Negative	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , negative	LC-MS/MS	splash10-0002-0090000000-5ba2996dd1e65cd9aef6
MS/MS Spectrum - , negative	LC-MS/MS	splash10-0udj-0298000000-0bbbfc4f4a4f06eabd19
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0udi-1249000000-89e125689ac3c8ab2522
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0pb9-0079000000-3ec59b6cb85bb16ee539
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0pb9-0059000000-23c28bc86f2cb99c8879

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Aryl hydrocarbon receptor

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Agonist

General Function

Transcription regulatory region dna binding

Specific Function

Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes...

Gene Name

AHR

Uniprot ID

P35869

Uniprot Name

Aryl hydrocarbon receptor

Molecular Weight

96146.705 Da

References

1. Zhang S, Qin C, Safe SH: Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ Health Perspect. 2003 Dec;111(16):1877-82. [Article]
2. Ciolino HP, Wang TT, Yeh GC: Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity. Cancer Res. 1998 Jul 1;58(13):2754-60. [Article]
3. Lee J, Song KM, Jung CH: Diosmin restores the skin barrier by targeting the aryl hydrocarbon receptor in atopic dermatitis. Phytomedicine. 2021 Jan;81:153418. doi: 10.1016/j.phymed.2020.153418. Epub 2020 Nov 25. [Article]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 16, 2014 18:43 / Updated at April 16, 2021 04:48